TipHub

3,231

+18.95 +0.59%

29 Jul 2026

NSE Listed · Pharmaceuticals

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-06-16
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

NGL Fine Chem Limited (NGLFINE)

Volume: 3,535Avg Vol 1W: 5,267Avg Vol 1M: 8,86352W Range:1,175.53,349
Key Ratios
Checked 4h ago
Market Cap₹1,965 Cr
Current Price₹3,231
Previous Close₹3,212.05
High / Low (52w)₹3,349 / ₹1,175.5
Volume3,535
Avg Vol (1W)5,267
Avg Vol (1M)8,863
Stock P/E145.69
Book Value₹532.73
Dividend Yield0.06%
ROE14.62%
ROA8.81%
Revenue (TTM)
Revenue Growth8.73%
Profit Margin9.59%
Total Debt₹25 Cr
Shares Outstanding1 Cr
Face Value₹5
EPS (TTM)₹21.83
P/B5.97
Debt / Equity0.33
50 DMA₹2,967.99
200 DMA₹2,106.08
Day change+0.59%
SurveillanceLT-ASM · ASM 1
Price Chart
3,231 166.04% · 1Y
325611741.0L
2025-07-29
2026-07-29

20-day avg volume: 9K shares

Pros
  • Company is almost debt-free.
  • Revenue grew 15% YoY.
Cons
  • Stock trades at a high P/E of 146.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹91 Cr₹93 Cr₹89 Cr₹95 Cr₹104 Cr₹120 Cr₹128 Cr₹149 Cr
EBITDA₹12 Cr₹14 Cr₹2 Cr₹2 Cr₹13 Cr₹14 Cr₹22 Cr₹19 Cr
Net Profit₹9 Cr₹10 Cr₹1 Cr₹1 Cr₹9 Cr₹10 Cr₹16 Cr₹13 Cr
EPS
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹91 Cr₹87 Cr₹377 Cr₹93 Cr₹101 Cr₹117 Cr₹126 Cr₹145 Cr
EBITDA₹14 Cr₹2 Cr₹30 Cr₹1 Cr₹11 Cr₹12 Cr₹20 Cr₹16 Cr
Net Profit₹10 Cr₹1 Cr₹21 Cr₹-1 Cr₹8 Cr₹8 Cr₹15 Cr₹11 Cr
EPS34.19
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹142 Cr₹154 Cr₹207 Cr₹277 Cr₹287 Cr₹356 Cr₹433 Cr
Total Liabilities₹50 Cr₹55 Cr₹53 Cr₹74 Cr₹65 Cr₹93 Cr₹151 Cr
Equity₹92 Cr₹99 Cr₹154 Cr₹203 Cr₹223 Cr₹263 Cr₹282 Cr
Total Debt
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹16 Cr₹24 Cr₹48 Cr₹31 Cr₹42 Cr₹34 Cr₹42 Cr
Investing₹-10 Cr₹-20 Cr₹-25 Cr₹-14 Cr₹-27 Cr₹-27 Cr₹-35 Cr
Financing₹0 Cr₹-1 Cr₹-1 Cr₹-1 Cr₹-1 Cr₹-1 Cr₹-1 Cr
Free Cash Flow₹16 Cr₹24 Cr₹48 Cr₹31 Cr₹42 Cr₹34 Cr₹42 Cr
Shareholding
Promoter 72.49% Institutions 0.07% Public 27.43%
Efficiency & Working Capital
ROCE9.3%
Interest Coverage9.5
Dividend Payout
Debtor Days81 d
Inventory Days51 d
Payable Days57 d
Cash Conversion Cycle75 d
Working Capital Days132 d
Shareholding Details

As of 2026-06-30

Promoter72.5%
FII0%
DII0%
Institutions0.1%
Public27.4%
Promoter Pledge0%
No. of Shareholders13,393
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters73.1%73.1%72.7%72.7%72.7%72.7%72.7%72.7%72.7%72.7%72.7%72.5%
FIIs0%0%0.1%0%0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public26.9%26.9%27.2%27.2%27.2%27.2%27.3%27.3%27.3%27.3%27.2%27.4%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders17,62316,41015,04114,60814,57514,11014,38614,01013,38712,83412,51613,393
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Rajesh Narayan LawandeShareholding of Promoter and Promoter Group21.9%13,52,366
Rahul Jayant NachaneShareholding of Promoter and Promoter Group17.5%10,83,450
Sunita Sandeep PotdarShareholding of Promoter and Promoter Group13.1%8,11,510
Ajita Rahul NachaneShareholding of Promoter and Promoter Group11.6%7,13,449
Pci Ferrmone Chemicals India Private LimitedShareholding of Promoter and Promoter Group8.4%5,17,871
Pushpa Narayan LawandeShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Dhananjay N MungaleChairman & Independent Directo2025
Rahul J NachaneED / MD / Promoter2025
Rajesh N LawandeED / WTD / CFO / Promoter2025
Jayaram SitaramIndependent Non Exe. Director2025
Ajita NachaneIndependent Non Exe. Director2025
Sarala MenonIndependent Non Exe. Director2025
S R DeoIndependent Non Exe. Director2025
Shivam GharatCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹5533
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-18Dividend (1.75/- per share)Final
dividend2026-08-18₹1.75 (35%)Final
dividend2025-08-12₹1.75 (35%)Final
forthcomingBook ClosureAGM
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202545106052
202512000013
202529105035
Insider / Designated-Person Trades

9 recent disclosure(s)

SUNITA POTDARDisposal · 1,069
SUNITA POTDARDisposal · 368
SUNITA POTDARDisposal · 1,281
SUNITA POTDARDisposal · 1,190
SUNITA POTDARDisposal · 282
SUNITA POTDARDisposal · 1,364
Substantial Acquisitions (SAST)

8 disclosure(s)

Market19/02/2024 · 20,000
Market15/09/2023 · 636
Market13/09/2023 · 474
Market12/09/2023 · 10
Market11/09/2023 · 4,191
Market08/09/2023 · 4,823
Company Information
Incorporated1981
ChairmanDhananjay N Mungale
AuditorManek & Associates
Investor Email[email protected]
🌐 www.nglfinechem.com

📍 301 E Square Subhash Road, Vile Parle (East), Mumbai, Maharashtra, 400057

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search